Clinical Trial

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-11-08; most recent amendment 2024-12-16.
Status change: Suspended → Recruiting 2024-12-16
Status change: Recruiting → Suspended 2023-11-15
Status change: Not Yet Recruiting → Recruiting 2023-01-17
Trial Details
NCT Number NCT05615974
Lead Sponsor LaNova Medicines Limited
Conditions Malignant Tumors
Enrollment 139 participants
Start Date 2023-01-11
Primary Completion 2027-01-11 (estimated)
Study Completion 2028-01-11 (estimated)
Updated on ClinicalTrials.gov 2024-12-19